The DOI matches its Crossref record; 115 of the 115 references it cites were found in a registry or an index.
European Society of Endocrinology Clinical Practice Guidelines for the management of aggressive pituitary tumours and carcinomas
Open accessAbstract
Background: Pituitary tumours are common and easily treated by surgery or medical treatment in most cases. However, a small subset of pituitary tumours does not respond to standard medical treatment and presents with multiple local recurrences (aggressive pituitary tumours) and in rare occasion with metastases (pituitary carcinoma). The present European Society of Endocrinology (ESE) guideline aims to provide clinical guidance on diagnosis, treatment and follow-up in aggressive pituitary tumours and carcinomas. Methods: We decided upfront, while acknowledging that literature on aggressive pituitary tumours and carcinomas is scarce, to systematically review the literature according to the GRADE (Grading of Recommendations Assessment, Development and Evaluation) system. The review focused primarily on first- and second-line treatment in aggressive pituitary tumours and carcinomas. We included 14 single-arm cohort studies (total number of patients = 116) most on temozolomide treatment ( n = 11 studies, total number of patients = 106). A positive treatment effect was seen in 47% (95% CI: 36–58%) of temozolomide treated. Data from the recently performed ESE survey on aggressive pituitary tumours and carcinomas (165 patients) were also used as backbone for the guideline. Selected recommendation: (i) Patients with aggressive pituitary tumours should be managed by a multidisciplinary expert team. (ii) Histopathological analyses including pituitary hormones and proliferative markers are needed for correct tumour classification. (iii) Temozolomide monotherapy is the first-line chemotherapy for aggressive pituitary tumours and pituitary carcinomas after failure of standard therapies; treatment evaluation after 3 cycles allows identification of responder and non-responder patients. (iv) In patients responding to first-line temozolomide, we suggest continuing treatment for at least 6 months in total. Furthermore, the guideline offers recommendations for patients who recurred after temozolomide treatment, for those who did not respond to temozolomide and for patients with systemic metastasis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma
Hegi, M. E., Diserens, A.-C., Gorlia, T., Hamou, M.-F., de Tribolet, N., Weller, M., Kros, J. M., Hainfellner, J. A., Mason, W., Mariani, L., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043331 · Cited by 7,405
Diagnosis and treatment of hyperprolactinemia: an Endocrine Society Clinical Practice Guideline
Melmed, S., Casanueva, F. F., Hoffman, A. R., Kleinberg, D. L., Montori, V. M., Schlechte, J. A., & Wass, J. A. H. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-1692 · Cited by 1,844
Acromegaly: An Endocrine Society Clinical Practice Guideline
Katznelson, L., Laws, E. R., Melmed, S., Molitch, M. E., Murad, M. H., Utz, A., & Wass, J. A. H. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-2700 · Cited by 1,786
Andrews, J. C., Schünemann, H. J., Oxman, A. D., Pottie, K., Meerpohl, J. J., Coello, P. A., Rind, D., Montori, V. M., Brito, J. P., Norris, S., et al. (2013) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2013.02.003 · Cited by 1,315
Treatment of Cushing's syndrome: an Endocrine Society clinical practice guideline
Nieman, L. K., Biller, B. M. K., Findling, J. W., Murad, M. H., Newell-Price, J., Savage, M. O., & Tabarin, A. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-1818 · Cited by 1,270
Pathology and genetics of tumours of endocrine organs
DeLellis, R. A. (2004) · Cited by 1,122
Fernandez, A., Karavitaki, N., & Wass, J. A. H. (2010) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2009.03667.x · Cited by 1,115
Dose-Dense Temozolomide for Newly Diagnosed Glioblastoma: A Randomized Phase III Clinical Trial
Gilbert, M. R., Wang, M., Aldape, K. D., Stupp, R., Hegi, M. E., Jaeckle, K. A., Armstrong, T. S., Wefel, J. S., Won, M., Blumenthal, D. T., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.49.6968 · Cited by 1,063
Ciric, I., Ragin, A., Baumgartner, C., & Pierce, D. (1997) · Neurosurgery · doi:10.1097/00006123-199702000-00001 · Cited by 1,029
High Prevalence of Pituitary Adenomas: A Cross-Sectional Study in the Province of Liège, Belgium
Daly, A. F., Rixhon, M., Adam, C., Dempegioti, A., Tichomirowa, M. A., & Beckers, A. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-1668 · Cited by 1,025
Treatment of Acromegaly with the Growth Hormone–Receptor Antagonist Pegvisomant
Trainer, P. J., Drake, W. M., Katznelson, L., Freda, P. U., Herman-Bonert, V., van der Lely, A. J., Dimaraki, E. V., Stewart, P. M., Friend, K. E., Vance, M. L., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200004203421604 · Cited by 879
Imhof, A., Brunner, P., Marincek, N., Briel, M., Schindler, C., Rasch, H., Mäcke, H. R., Rochlitz, C., Müller-Brand, J., & Walter, M. A. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.7873 · Cited by 641
A 12-month phase 3 study of pasireotide in Cushing's disease
Colao, A., Petersenn, S., Newell-Price, J., Findling, J. W., Gu, F., Maldonado, M., Schoenherr, U., Dipl.-Biol., Mills, D., Salgado, L. R., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1105743 · Cited by 628
Self-citationSaeger, W., Lüdecke, D. K., Buchfelder, M., Fahlbusch, R., Quabbe, H.-J., & Petersenn, S. (2007) · European Journal of Endocrinology · doi:10.1530/eje.1.02326 · Cited by 583
Self-citationChatzellis, E., Alexandraki, K. I., Androulakis, I. I., & Kaltsas, G. (2015) · Neuroendocrinology · doi:10.1159/000371806 · Cited by 572
HYPOPRONOS, T. M. O., Trouillas, J., Roy, P., Sturm, N., Dantony, E., Cortet-Rudelli, C., Viennet, G., Bonneville, J.-F., Assaker, R., Auger, C., et al. (2013) · Acta Neuropathologica · doi:10.1007/s00401-013-1084-y · Cited by 545
Self-citationMirimanoff, R.-O., Gorlia, T., Mason, W., Van den Bent, M. J., Kortmann, R.-D., Fisher, B., Reni, M., Brandes, A. A., Curschmann, J., Villa, S., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.5963 · Cited by 509
Temozolomide as Monotherapy Is Effective in Treatment of Advanced Malignant Neuroendocrine Tumors
Ekeblad, S., Sundin, A., Janson, E. T., Welin, S., Granberg, D., Kindmark, H., Dunder, K., Kozlovacki, G., Örlefors, H., Sigurd, M., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2053 · Cited by 473
Incidence of Pituitary Adenomas in Northern Finland in 1992–2007
Raappana, A., Koivukangas, J., Ebeling, T., & Pirilä, T. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-0537 · Cited by 470
Bollerslev, J., Rejnmark, L., Marcocci, C., Shoback, D. M., Sitges-Serra, A., van Biesen, W., & Dekkers, O. M. (2015) · European Journal of Endocrinology · doi:10.1530/eje-15-0628 · Cited by 462
Self-citationPasireotide Versus Octreotide in Acromegaly: A Head-to-Head Superiority Study
Colao, A., Bronstein, M. D., Freda, P., Gu, F., Shen, C.-C., Gadelha, M., Fleseriu, M., van der Lely, A. J., Farrall, A. J., Hermosillo Reséndiz, K., et al. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-2480 · Cited by 400
Minniti, G., Traish, D., Ashley, S., Gonsalves, A., & Brada, M. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-1152 · Cited by 377
Beckers, A., Aaltonen, L. A., Daly, A. F., & Karhu, A. (2013) · Endocrine Reviews · doi:10.1210/er.2012-1013 · Cited by 360
Long-Acting Somatostatin Analog Therapy of Acromegaly: A Meta-Analysis
Freda, P. U., Katznelson, L., van der Lely, A. J., Reyes, C. M., Zhao, S., & Rabinowitz, D. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-0260 · Cited by 346
Thapar, K., Scheithauer, B. W., Kovacs, K., Pernicone, P. J., & Laws, E. R. (1996) · Neurosurgery · doi:10.1097/00006123-199604000-00027 · Cited by 321
Aggressive pituitary adenomas—diagnosis and emerging treatments
Di Ieva, A., Rotondo, F., Syro, L. V., Cusimano, M. D., & Kovacs, K. (2014) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2014.64 · Cited by 318
Beck-Peccoz, P., Lania, A., Beckers, A., Chatterjee, K., & Wemeau, J.-L. (2013) · European Thyroid Journal · doi:10.1159/000351007 · Cited by 283
Resistance to Somatostatin Analogs in Acromegaly
Colao, A., Auriemma, R. S., Lombardi, G., & Pivonello, R. (2011) · Endocrine Reviews · doi:10.1210/er.2010-0002 · Cited by 257
EGFR as a therapeutic target for human, canine, and mouse ACTH-secreting pituitary adenomas
Fukuoka, H., Cooper, O., Ben-Shlomo, A., Mamelak, A., Ren, S.-G., Bruyette, D., & Melmed, S. (2011) · Journal of Clinical Investigation · doi:10.1172/jci60417 · Cited by 254
van der Lely, A. J., Biller, B. M. K., Brue, T., Buchfelder, M., Ghigo, E., Gomez, R., Hey-Hadavi, J., Lundgren, F., Rajicic, N., Strasburger, C. J., et al. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-2508 · Cited by 252
The Antitumoral Effects of Somatostatin Analog Therapy in Acromegaly
Bevan, J. S. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-1093 · Cited by 249
Radiation Therapy in the Management of Pituitary Adenomas
Loeffler, J. S., & Shih, H. A. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-0251 · Cited by 239
Assié, G., Bahurel, H., Coste, J., Silvera, S., Kujas, M., Dugué, M.-A., Karray, F., Dousset, B., Bertherat, J., Legmann, P., et al. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-1328 · Cited by 230
Raverot, G., Sturm, N., de Fraipont, F., Muller, M., Salenave, S., Caron, P., Chabre, O., Chanson, P., Cortet-Rudelli, C., Assaker, R., et al. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-0644 · Cited by 228
Self-citationSheehan, J. P., Starke, R. M., Mathieu, D., Young, B., Sneed, P. K., Chiang, V. L., Lee, J. Y. K., Kano, H., Park, K.-J., Niranjan, A., et al. (2013) · Journal of Neurosurgery · doi:10.3171/2013.3.jns12766 · Cited by 227
Mercado, M., Borges, F., Bouterfa, H., Chang, T., Chervin, A., Farrall, A. J., Patocs, A., Petersenn, S., Podoba, J., Safari, M., et al. (2007) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2007.02825.x · Cited by 214
Self-citationTHERAPY OF ENDOCRINE DISEASE: The challenges in managing giant prolactinomas
Maiter, D., & Delgrange, E. (2014) · European Journal of Endocrinology · doi:10.1530/eje-14-0013 · Cited by 197
Radiotherapy for non‐functioning pituitary tumours
Gittoes, Bates, Tse, Bullivant, Sheppard, Clayton, & Stewart (1998) · Clinical Endocrinology · doi:10.1046/j.1365-2265.1998.00393.x · Cited by 194
Bengtsson, D., Schrøder, H. D., Andersen, M., Maiter, D., Berinder, K., Feldt Rasmussen, U., Rasmussen, Å. K., Johannsson, G., Hoybye, C., van der Lely, A. J., et al. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-4350 · Cited by 194
Self-citationDelgrange, E., Daems, T., Verhelst, J., Abs, R., & Maiter, D. (2009) · European Journal of Endocrinology · doi:10.1530/eje-09-0012 · Cited by 194
Prospective Study of High-Dose Cabergoline Treatment of Prolactinomas in 150 Patients
Ono, M., Miki, N., Kawamata, T., Makino, R., Amano, K., Seki, T., Kubo, O., Hori, T., & Takano, K. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-2758 · Cited by 191
Caron, P. J., Bevan, J. S., Petersenn, S., Flanagan, D., Tabarin, A., Prévost, G., Maisonobe, P., Clermont, A., & on behalf of the PRIMARYS Investigators (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-3318 · Cited by 182
Self-citationTemozolomide: a novel treatment for pituitary carcinoma
Lim, S., Shahinian, H., Maya, M. M., Yong, W., & Heaney, A. P. (2006) · The Lancet Oncology · doi:10.1016/s1470-2045(06)70728-8 · Cited by 181
Self-citationMedical treatment of prolactinomas
Colao, A. A. L., & Savastano, S. (2011) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2011.37 · Cited by 175
Tichomirowa, M. A., Barlier, A., Daly, A. F., Jaffrain-Rea, M.-L., Ronchi, C., Yaneva, M., Urban, J. D., Petrossians, P., Elenkova, A., Tabarin, A., et al. (2011) · European Journal of Endocrinology · doi:10.1530/eje-11-0304 · Cited by 175
ENDOCRINOLOGY IN PREGNANCY: Management of the pregnant patient with a prolactinoma
Molitch, M. E. (2015) · European Journal of Endocrinology · doi:10.1530/eje-14-0848 · Cited by 170
Iacovazzo, D., Carlsen, E., Lugli, F., Chiloiro, S., Piacentini, S., Bianchi, A., Giampietro, A., Mormando, M., Clear, A. J., Doglietto, F., et al. (2016) · European Journal of Endocrinology · doi:10.1530/eje-15-0832 · Cited by 168
Long-term response of pituitary carcinoma to temozolomide
Fadul, C. E., Kominsky, A. L., Meyer, L. P., Kingman, L. S., Kinlaw, W. B., Rhodes, C. H., Eskey, C. J., & Simmons, N. E. (2006) · Journal of neurosurgery · doi:10.3171/jns.2006.105.4.621 · Cited by 167
Blevins, L. S., Christy, J. H., Khajavi, M., & Tindall, G. T. (1998) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.83.1.4525 · Cited by 167
Management of medically refractory prolactinoma
Molitch, M. E. (2014) · Journal of Neuro-Oncology · doi:10.1007/s11060-013-1270-8 · Cited by 165
Aggressive pituitary tumours: the role of temozolomide and the assessment of MGMT status
McCormack, A. I., Wass, J. A. H., & Grossman, A. B. (2011) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.2011.02520.x · Cited by 161
Self-citationBush, Z. M., Longtine, J. A., Cunningham, T. L., Schiff, D., Jane, J. A., Vance, M. L., Thorner, M. O., Laws, E. R., & Lopes, M. B. S. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-0441 · Cited by 153
Novel Genetic Causes of Pituitary Adenomas
Caimari, F., & Korbonits, M. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0452 · Cited by 151
Landscape of Genomic Alterations in Pituitary Adenomas
Bi, W. L., Horowitz, P. M., Greenwald, N. F., Abedalthagafi, M., Agarwalla, P. K., Gibson, W. J., Mei, Y., Schumacher, S. E., Ben‐David, U., Chevalier, A. A., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0790 · Cited by 147
Lasolle, H., Cortet, C., Castinetti, F., Cloix, L., Caron, P. J., Delemer, B., Desailloud, R., Jublanc, C., Lebrun‐Frénay, C., Sadoul, J., et al. (2017) · European Journal of Endocrinology · doi:10.1530/eje-16-0979 · Cited by 145
Self-citationAnti-VEGF therapy in pituitary carcinoma
Ortiz, L. D., Syro, L. V., Scheithauer, B. W., Erşen, A., Uribe, H., Fadul, C. E., Rotondo, F., Horváth, É., & Kovács, K. (2011) · Pituitary · doi:10.1007/s11102-011-0346-8 · Cited by 142
Ben-Shlomo, A., & Cooper, O. B. (2018) · Pituitary · doi:10.1007/s11102-018-0864-8 · Cited by 139
Miermeister, C. P., Petersenn, S., Buchfelder, M., Fahlbusch, R., Lüdecke, D. K., Hölsken, A., Bergmann, M., Knappe, U. J., Hans, V., Flitsch, J., et al. (2015) · Acta Neuropathologica Communications · doi:10.1186/s40478-015-0229-8 · Cited by 136
Self-citationTemozolomide therapy in patients with aggressive pituitary adenomas or carcinomas
Losa, M., Bogazzi, F., Cannavò, S., Ceccato, F., Curtò, L., Marinis, L. D., Iacovazzo, D., Lombardi, G., Mantovani, G., Mazza, E. A., et al. (2015) · Journal of Neuro-Oncology · doi:10.1007/s11060-015-1991-y · Cited by 136
Casar‐Borota, O., Heck, A., Schulz, S., Nesland, J. M., Ramm‐Pettersen, J., Lekva, T., Alafuzoff, I. I., & Bollerslev, J. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-2145 · Cited by 134
HIROHATA, T., Asano, K., Ogawa, Y., Takano, S., Amano, K., Isozaki, O., Iwai, Y., Sakata, K., Fukuhara, N., Nishioka, H., et al. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-2924 · Cited by 129
The pathophysiology of pituitary adenomas
Dworakowska, D., & Grossman, A. B. (2009) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2009.05.004 · Cited by 118
Thyrotropin-secreting pituitary adenomas: epidemiology, diagnosis, and management
Amlashi, F. G., & Tritos, N. A. (2016) · Endocrine · doi:10.1007/s12020-016-0863-3 · Cited by 117
Salenave, S., Ancelle, D., Bahougne, T., Raverot, G., Kamenický, P., Bouligand, J., Guiochon‐Mantel, A., Linglart, A., Souchon, P., Nicolino, M. P., et al. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-3670 · Cited by 115
Self-citationCerovac, V., Garcia, J. L. M., Rubinfeld, H., Buchfelder, M., Losa, M., Florio, T., Páez-Pereda, M., Stalla, G. K., & Theodoropoulou, M. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-2951 · Cited by 115
Temozolomide: a novel oral alkylating agent
Danson, S. J., & Middleton, M. R. (2001) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.1.1.13 · Cited by 113
In vitro and In vivo Radiosensitization Induced by the DNA Methylating Agent Temozolomide
Kil, W. J., Cerna, D., Burgan, W. E., Beam, K., Carter, D., Steeg, P. S., Tofilon, P. J., & Camphausen, K. A. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1856 · Cited by 112
Syro, L. V., Uribe, H., Penagos, L. C., Ortiz, L. D., Fadul, C. E., Horváth, É., & Kovács, K. (2006) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2006.02653.x · Cited by 110
New targeted therapies in pituitary carcinoma resistant to temozolomide
Jouanneau, E., Wierinckx, A., Ducray, F., Favrel, V., Borson‐Chazot, F., Honnorat, J., Trouillas, J., & Raverot, G. (2011) · Pituitary · doi:10.1007/s11102-011-0341-0 · Cited by 109
Self-citationTreatment paradigms for pituitary adenomas: defining the roles of radiosurgery and radiation therapy
Ding, D., Starke, R. M., & Sheehan, J. P. (2013) · Journal of Neuro-Oncology · doi:10.1007/s11060-013-1262-8 · Cited by 109
Kuyumcu, S., Özkan, Z. G., Şanlı, Y., Yılmaz, E., Mudun, A., Adalet, İ., & Ünal, S. N. (2013) · Annals of Nuclear Medicine · doi:10.1007/s12149-013-0718-4 · Cited by 108
Tampourlou, M., Ntali, G., Ahmed, S. K., Arlt, W., Ayuk, J., Byrne, J. V., Chavda, S. V., Cudlip, S., Gittoes, N. J. L., Grossman, A. B., et al. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-4061 · Cited by 107
Chinezu, L., Vasiljevic, A., Jouanneau, E., François, P., Borda, A., Trouillas, J., & Raverot, G. (2014) · Human Pathology · doi:10.1016/j.humpath.2013.08.007 · Cited by 106
Self-citationMinniti, G. C., Esposito, V., Piccirilli, M., Fratticci, A., Santoro, A., & Jaffrain‐Rea, M. (2005) · European Journal of Endocrinology · doi:10.1530/eje.1.02030 · Cited by 105
Medical Management of Thyrotropin-Secreting Pituitary Adenomas
Beck‐Peccoz, P., & Persani, L. (2002) · Pituitary · doi:10.1023/a:1022360414062 · Cited by 98
Dose‐dense temozolomide regimens
Neyns, B., Tosoni, A., Hwu, W., & Reardon, D. A. (2010) · Cancer · doi:10.1002/cncr.25035 · Cited by 98
Delgrange, E., Maiter, D. M., & Donckier, J. E. (1996) · European Journal of Endocrinology · doi:10.1530/eje.0.1340454 · Cited by 97
Management of aggressive pituitary adenomas and pituitary carcinomas
Heaney, A. P. (2014) · Journal of Neuro-Oncology · doi:10.1007/s11060-014-1413-6 · Cited by 97
Self-citationTemozolomide in the management of dopamine agonist–resistant prolactinomas
Whitelaw, B., Dorota Dworakowska, B., Thomas, N. W., Barazi, S. A., Riordan‐Eva, P., King, A. P., Hampton, T., Landau, D., LIPSCOMB, D. W., Buchanan, C. R., et al. (2012) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2012.04373.x · Cited by 96
Effect of Everolimus on Cell Viability in Nonfunctioning Pituitary Adenomas
Zatelli, M. C., Minoia, M., Filieri, C., Tagliati, F., Buratto, M., Ambrosio, M. R., Lapparelli, M., Scanarini, M., & Uberti, E. C. D. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-1641 · Cited by 92
Predictors and rates of treatment-resistant tumor growth in acromegaly
BESSER, G. M., Burman, P., & Daly, A. (2005) · European Journal of Endocrinology · doi:10.1530/eje.1.01968 · Cited by 88
Self-citationZacharia, B. E., Gulati, A. P., Bruce, J. N., Carminucci, A. S., Wardlaw, S. L., Siegelin, M. D., Remotti, H. E., Lignelli, A., & Fine, R. L. (2013) · Neurosurgery · doi:10.1227/neu.0000000000000251 · Cited by 88
Carlson, B. L., Grogan, P. T., Mladek, A. C., Schroeder, M. A., Kitange, G. J., Decker, P. A., Giannini, C., Wu, W., Ballman, K. V., James, C. D., et al. (2009) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2009.04.026 · Cited by 87
Prolactinoma ErbB receptor expression and targeted therapy for aggressive tumors
Cooper, O. B., Mamelak, A. N., Bannykh, S., Carmichael, J. D., Bonert, V. S., Lim, S. W., Cook‐Wiens, G., & Ben-Shlomo, A. (2013) · Endocrine · doi:10.1007/s12020-013-0093-x · Cited by 84
Gorshtein, A., Rubinfeld, H., Kendler, E., Theodoropoulou, M., Cerovac, V., Stalla, G. K., Cohen, Z. R., Hadani, M., & Shimon, I. (2009) · Endocrine Related Cancer · doi:10.1677/erc-08-0269 · Cited by 84
Barbagallo, G. M. V., Paratore, S., Caltabiano, R., Palmucci, S., Parra, H. J. S., Privitera, G., Motta, F., Lanzafame, S., Scaglione, G., Longo, A., et al. (2014) · Neurosurgical FOCUS · doi:10.3171/2014.9.focus14502 · Cited by 79
Cooper, O. B. (2014) · Pituitary · doi:10.1007/s11102-014-0624-3 · Cited by 75
Delgrange, E., Raverot, G., Bex, M., Burman, P., Decoudier, B., Devuyst, F., Feldt‐Rasmussen, U., Andersen, M., & Maiter, D. M. (2013) · European Journal of Endocrinology · doi:10.1530/eje-13-0503 · Cited by 74
Self-citationKwekkeboom, D. J., de Herder, W. W., & Krenning, E. P. (2011) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2010.12.003 · Cited by 73
Kuhn, E., & Chanson, P. (2016) · Pituitary · doi:10.1007/s11102-016-0782-6 · Cited by 73
Lee, M., Wiedemann, T., Gross, C., Leinhäuser, I., Roncaroli, F., Braren, R., & Pellegata, N. S. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0288 · Cited by 71
Fukuoka, H., Cooper, O. B., Mizutani, J., Tong, Y., Ren, S.-G., Bannykh, S., & Melmed, S. K. (2010) · Molecular Endocrinology · doi:10.1210/me.2010-0353 · Cited by 71
Pituitary tumours: The sst/D2 receptors as molecular targets
Hofland, L. J., Feelders, R. A., de Herder, W. W., & Lamberts, S. W. J. (2010) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2010.04.020 · Cited by 70
Baldari, S., Ferraù, F., Alafaci, C., Herberg, A., Granata, F., Militano, V., Salpietro, F. M., Trimarchi, F., & Cannavò, S. (2012) · Pituitary · doi:10.1007/s11102-011-0373-5 · Cited by 64
Ceccato, F., Lombardi, G., Manara, R., Emanuelli, E., Denaro, L., Milanese, L., Gardiman, M. P., Bertorelle, R., Scanarini, M., D’Avella, D., et al. (2015) · Journal of Neuro-Oncology · doi:10.1007/s11060-014-1702-0 · Cited by 61
Robenshtok, E., Benbassat, C. A., Hirsch, D., Tzvetov, G., Cohen, Z. R., Masri‐Iraqi, H., Gorshtein, A., Toledano, Y., & Shimon, I. (2013) · Endocrine Practice · doi:10.4158/ep13182.or · Cited by 59
Burman, P., Engström, B. E., Ekman, B., Karlsson, F. A., Schwarcz, E., & Wahlberg, J. (2015) · European Journal of Endocrinology · doi:10.1530/eje-15-0807 · Cited by 59
Self-citationKatznelson, L. (2013) · Journal of Clinical Endocrinology and Metabolism · doi:10.1210/jc.2013-1497 · Cited by 52
Peptide receptor radionuclide therapy in a patient with disabling non-functioning pituitary adenoma
Komor, J., Reubi, J. C., & Christ, E. (2013) · Pituitary · doi:10.1007/s11102-013-0494-0 · Cited by 50
Growth modelling of non-functioning pituitary adenomas in patients referred for surgery
Honegger, J. B., Zimmermann, S., Psaras, T., Petrick, M., Mittelbronn, M. G. A., Ernemann, U., Reincke, M., & Dietz, K. (2008) · European Journal of Endocrinology · doi:10.1530/eje-07-0502 · Cited by 49
Burman, P., van Beek, A. P., Biller, B. M. K., Camacho‐Hübner, C., & Mattsson, A. F. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-3402 · Cited by 49
Self-citationTreatment of a pituitary metastasis from a neuroendocrine tumour: case report and literature review
Goglia, U., Ferone, D., Sidoti, M., Spaziante, R., Dadati, P., Ravetti, J.-L., Villa, G., Bodei, L., Paganelli, G., Minuto, F. M., et al. (2007) · Pituitary · doi:10.1007/s11102-007-0038-6 · Cited by 44
Biological and radiological exploration and management of non-functioning pituitary adenoma
Raverot, G., Assié, G., Cotton, F., Cogne, M., Boulin, A., d’Herbomez, M., Bonneville, J. F., & Massart, C. (2015) · Annales d Endocrinologie · doi:10.1016/j.ando.2015.04.005 · Cited by 42
Self-citationMortality following pituitary radiotherapy
Ayuk, J., & Stewart, P. M. (2008) · Pituitary · doi:10.1007/s11102-007-0083-1 · Cited by 41
Pituitary Tumors in the Elderly
Kurosaki, M., Saeger, W., & Lüdecke, D. K. (2001) · Pathology - Research and Practice · doi:10.1078/0344-0338-00117 · Cited by 40
Tufton, N., Shapiro, L., Srirangalingam, U., Richards, P. S., Sahdev, A., Kumar, A., McAndrew, L., Martin, L., Berney, D. M., Monson, J. P., et al. (2016) · Clinical Endocrinology · doi:10.1111/cen.13246 · Cited by 39
Waligórska‐Stachura, J., Gut, P., Sawicka‐Gutaj, N., et al. (2015) · Journal of neurosurgery · doi:10.3171/2015.6.jns15363 · Cited by 38
Pituitary Tumor Management in Pregnancy
Araújo, P. B., Neto, L. V., & Gadelha, M. R. (2014) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2014.10.015 · Cited by 37
Pregnancy Does Not Accelerate Corticotroph Tumor Progression in Nelson's Syndrome
Jornayvaz, F. R., Assié, G., Bienvenu-Perrard, M., Coste, J., Guignat, L., Bertherat, J. Y., Silvera, S., BERTAGNA, X. Y., & Legmann, P. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-2235 · Cited by 29
Chanal, M., Chevallier, P., Raverot, V., Fonteneau, G., Lucia, K. E., Garcia, J. L. M., Rachwan, A., Jouanneau, E., Trouillas, J., Honnorat, J., et al. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0891 · Cited by 27
Self-citationCornell, R. F., Kelly, D. F., Bordo, G., Carroll, T. B., Duong, H. T., Kim, J. J., Takasumi, Y., Thomas, J. P., Wong, Y. L., & Findling, J. W. (2013) · Case Reports in Endocrinology · doi:10.1155/2013/675298 · Cited by 17
Norberg, L., Johansson, R., & Rasmuson, T. (2010) · Acta Oncologica · doi:10.3109/02841861003782025 · Cited by 16
Successful treatment of a child with a prolactin secreting macroadenoma with temozolomide
Felker, J. T., Patterson, B., Wrubel, D. M., & Janss, A. J. (2016) · Journal of Pediatric Endocrinology and Metabolism · doi:10.1515/jpem-2016-0159 · Cited by 16
Paradoxical and atypical responses to pasireotide in aggressive ACTH-secreting pituitary tumors
Greenman, Y., & Stern, N. (2016) · Pituitary · doi:10.1007/s11102-016-0755-9 · Cited by 12
Dekkers, O. M., Burman, P., & _, _. (2015) · European Journal of Endocrinology · doi:10.1530/eje-15-0625 · Cited by 9
Self-citation
Cited by
Rindi, G., Klimstra, D. S., Abedi-Ardekani, B., Asa, S. L., Bosman, F. T., Brambilla, E., Busam, K. J., de Krijger, R. R., Dietel, M., El-Naggar, A. K., et al. (2018) · Modern Pathology · doi:10.1038/s41379-018-0110-y · Cited by 1,163
Self-citationPituitary-Tumor Endocrinopathies
Melmed, S. (2020) · New England Journal of Medicine · doi:10.1056/nejmra1810772 · Cited by 604
Colao, A., Grasso, L. F. S., Giustina, A., Melmed, S., Chanson, P., Pereira, A. M., & Pivonello, R. (2019) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0071-6 · Cited by 396
Petersenn, S., Fleseriu, M., Casanueva, F. F., Giustina, A., Biermasz, N., Biller, B. M. K., Bronstein, M., Chanson, P., Fukuoka, H., Gadelha, M., et al. (2023) · Nature Reviews Endocrinology · doi:10.1038/s41574-023-00886-5 · Cited by 411
Self-citationPangenomic Classification of Pituitary Neuroendocrine Tumors
Neou, M., Villa, C., Armignacco, R., Jouinot, A., Raffin-Sanson, M.-L., Septier, A., Letourneur, F., Diry, S., Diedisheim, M., Izac, B., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2019.11.002 · Cited by 340
Metadata
- Authors
- Raverot, G., Burman, P., McCormack, A., Heaney, A., Petersenn, S., Popovic, V., Trouillas, J., Dekkers, O. M., & _, _.
- Venue
- European Journal of Endocrinology
- Publisher
- Oxford University Press (OUP)
- Published
- 2018-01
- Volume
- 178
- Issue
- 1
- Pages
- G1-G24
- ISSN
- 0804-4643 (ISSN-L)
- 1479-683X
- OpenAlex
- W2766825024
- Cited by
- 595
- References
- 115
- FWCI
- 31.36
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.